SCHEMBL1787096

SCHEMBL1787096

Oc1c(CN2CCCCC2)ccc2cccnc12

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.68
L3MBTL1 Q9Y468 6/20 0.68
TP53 P04637 6/20 0.68
ALOX15 P16050 6/20 0.68
ALOX12 P18054 4/20 0.68
HTT P42858 4/20 0.68
LMNA P02545 3/20 0.68
SMN1; SMN2 Q16637 3/20 0.68
CYP2C19 P33261 3/20 0.68
NPSR1 Q6W5P4 3/20 0.68
NPC1 O15118 2/20 0.68
CYP1A2 P05177 2/20 0.68
HSP90AA1 P07900 2/20 0.68
CYP2D6 P10635 2/20 0.68
RAB9A P51151 2/20 0.68
MPI P34949 1/20 0.68
ATM Q13315 1/20 0.68
BCHE P06276 1/20 0.66
MAPT P10636 3/20 0.64
NFKB1 P19838 2/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2237500 0.99 BCHE (0.67) KDM4EL3MBTL1TP53ALOX15ALOX12
Hydrochloric Acid SCHEMBL19437125 0.97 BCHE (0.66) KDM4EL3MBTL1TP53ALOX15ALOX12
SCHEMBL26241625 0.93 BCHE (0.74) KDM4EL3MBTL1TP53ALOX15ALOX12
SCHEMBL1240756 0.86 BCHE (0.63) KDM4EL3MBTL1TP53ALOX15ALOX12
SCHEMBL26241636 0.86 BCHE (0.70) KDM4EL3MBTL1TP53ALOX15ALOX12
SCHEMBL12530883 0.85 BCHE (0.62) KDM4EL3MBTL1TP53ALOX15ALOX12
SCHEMBL9976030 0.85 BCHE (0.69) KDM4EL3MBTL1TP53ALOX15ALOX12
SCHEMBL16825209 0.82 KDM4E (0.58) KDM4EL3MBTL1TP53ALOX15ALOX12
SCHEMBL17223776 0.82 KDM4E (0.65) KDM4EL3MBTL1TP53ALOX15ALOX12
SCHEMBL19437093 0.82 KDM4E (0.54) KDM4EL3MBTL1TP53ALOX15ALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3137079-A1 INHIBITORS OF JMJD2C AS ANTICANCER AGENTS The J. David Gladstone Institutes (US) 2017-03-08 EP claimed
US-20170044107-A1 Inhibitors of JMJD2C as Anticancer Agents THE J. DAVID GLADSTONE INSTITUTES 2017-02-16 US claimed
WO-2015167874-A1 INHIBITORS OF JMJD2C AS ANTICANCER AGENTS THE J. DAVID GLADSTONE INSTITUTES (US) 2015-11-05 WO claimed
EP-3440070-B1 MDR-REVERSING 8-HYDROXY-QUINOLINE DERIVATIVES MTA TERMESZETTUDOMANYI KUTATOKOEZPONT (HU) 2024-10-30 EP disclosed
EP-3137079-A1 INHIBITORS OF JMJD2C AS ANTICANCER AGENTS The J. David Gladstone Institutes (US) 2017-03-08 EP disclosed
US-20170044107-A1 Inhibitors of JMJD2C as Anticancer Agents THE J. DAVID GLADSTONE INSTITUTES 2017-02-16 US disclosed
WO-2015167874-A1 INHIBITORS OF JMJD2C AS ANTICANCER AGENTS THE J. DAVID GLADSTONE INSTITUTES (US) 2015-11-05 WO disclosed
US-9012899-B2 Electroluminescent metal complexes with nucleophilic carbene ligands BASF SE (DE) 2015-04-21 US disclosed
US-20130292660-A1 ELECTROLUMINESCENT METAL COMPLEXES WITH NUCLEOPHILIC CARBENE LIGANDS BASF SE (DE) 2013-11-07 US disclosed
US-8492749-B2 Electroluminescent metal complexes with nucleophilic carbene ligands BASF SE (DE) 2013-07-23 US disclosed
US-20120196853-A1 Novel Quinoline-Hepcidine Antagonists VIFOR (INTERNATIONAL) AG (CH) 2012-08-02 US disclosed
US-20070072968-A1 Metal salts of quinolinols and quinolinol derivatives as corrosion inhibitors HENKEL AG & CO. KGAA (DE) 2007-03-29 US disclosed
US-20070072968-A1 Metal salts of quinolinols and quinolinol derivatives as corrosion inhibitors HENKEL AG & CO. KGAA (DE) 2007-03-29 US disclosed
US-20070049722-A1 Quinolinols as fluxing and accelerating agents for underfill compositions HENKEL AG & CO. KGAA (DE) 2007-03-01 US disclosed
US-20070049722-A1 Quinolinols as fluxing and accelerating agents for underfill compositions HENKEL AG & CO. KGAA (DE) 2007-03-01 US disclosed
US-20070049665-A1 Quinolinols and quinolinol derivatives as adhesion promoters in die attach adhesives HENKEL AG & CO. KGAA (DE) 2007-03-01 US disclosed
US-20070049665-A1 Quinolinols and quinolinol derivatives as adhesion promoters in die attach adhesives HENKEL AG & CO. KGAA (DE) 2007-03-01 US disclosed
EP-1758163-A1 Quinolinols as fluxing and accelerating agents for underfill compositions National Starch and Chemical Investment Holding Corporation (US) 2007-02-28 EP disclosed
EP-1758164-A1 Quinolinols and quinolinol derivatives as adhesion promoters in die attach adhesives National Starch and Chemical Investment Holding Corporation (US) 2007-02-28 EP disclosed
WO-2006067074-A1 ELECTROLUMINESCENT METAL COMPLEXES WITH NUCLEOPHILIC CARBENE LIGANDS CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2006-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170044107-A1 Inhibitors of JMJD2C as Anticancer Agents KDM2A, KDM1B, KDM5C KDM4E 17/4885L3MBTL1 2157/4885TP53 269/4885
US-20120196853-A1 Novel Quinoline-Hepcidine Antagonists HAMP, SLC40A1, FTH1 KDM4E 3190/4885L3MBTL1 4549/4885TP53 4470/4885
US-20070049722-A1 Quinolinols as fluxing and accelerating agents for underfill compositions TAF1L, TAF1, TAF5 KDM4E 1292/4885L3MBTL1 3818/4885TP53 2606/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.